183 related articles for article (PubMed ID: 12614191)
21. Once-monthly ibandronate.
Dando TM; Noble S
Treat Endocrinol; 2005; 4(6):381-7; discussion 389-90. PubMed ID: 16318406
[TBL] [Abstract][Full Text] [Related]
22. Once-monthly oral ibandronate in postmenopausal osteoporosis: translation and updated review.
Rossini M; Viapiana O; Gatti D; Adami S
Clin Ther; 2009 Jul; 31(7):1497-510. PubMed ID: 19695399
[TBL] [Abstract][Full Text] [Related]
23. Ibandronate in profile: drug characteristics and clinical efficacy.
Reginster JY; Neuprez A; Bruyère O
Expert Opin Drug Metab Toxicol; 2008 Jul; 4(7):941-51. PubMed ID: 18624681
[TBL] [Abstract][Full Text] [Related]
24. Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis.
Recker R; Stakkestad JA; Chesnut CH; Christiansen C; Skag A; Hoiseth A; Ettinger M; Mahoney P; Schimmer RC; Delmas PD
Bone; 2004 May; 34(5):890-9. PubMed ID: 15121021
[TBL] [Abstract][Full Text] [Related]
25. [Ibandronate].
Tobinai M
Clin Calcium; 2011 Jan; 21(1):79-86. PubMed ID: 21187598
[TBL] [Abstract][Full Text] [Related]
26. The effect on bone mass and bone markers of different doses of ibandronate: a new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: a 1-year, randomized, double-blind, placebo-controlled dose-finding study.
Ravn P; Clemmesen B; Riis BJ; Christiansen C
Bone; 1996 Nov; 19(5):527-33. PubMed ID: 8922653
[TBL] [Abstract][Full Text] [Related]
27. Ibandronate: new options in the treatment of osteoporosis.
Adami S; Viapiana O
Drugs Today (Barc); 2003 Nov; 39(11):877-86. PubMed ID: 14702133
[TBL] [Abstract][Full Text] [Related]
28. Intravenous ibandronate injections given every three months: a new treatment option to prevent bone loss in postmenopausal women.
Stakkestad JA; Benevolenskaya LI; Stepan JJ; Skag A; Nordby A; Oefjord E; Burdeska A; Jonkanski I; Mahoney P;
Ann Rheum Dis; 2003 Oct; 62(10):969-75. PubMed ID: 12972476
[TBL] [Abstract][Full Text] [Related]
29. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study.
Miller PD; McClung MR; Macovei L; Stakkestad JA; Luckey M; Bonvoisin B; Reginster JY; Recker RR; Hughes C; Lewiecki EM; Felsenberg D; Delmas PD; Kendler DL; Bolognese MA; Mairon N; Cooper C
J Bone Miner Res; 2005 Aug; 20(8):1315-22. PubMed ID: 16007327
[TBL] [Abstract][Full Text] [Related]
30. Optimizing the management of postmenopausal osteoporosis with bisphosphonates: the emerging role of intermittent therapy.
Miller PD
Clin Ther; 2005 Apr; 27(4):361-76. PubMed ID: 15922811
[TBL] [Abstract][Full Text] [Related]
31. [Ibandronate as a new therapeutic agent for osteoporosis].
Goto H; Inaba M
Clin Calcium; 2005 Jan; 15(1):15-7. PubMed ID: 15632467
[TBL] [Abstract][Full Text] [Related]
32. Osteoporosis treatment: why ibandronic acid?
Rossini M; Orsolini G; Adami S; Kunnathully V; Gatti D
Expert Opin Pharmacother; 2013 Jul; 14(10):1371-81. PubMed ID: 23650954
[TBL] [Abstract][Full Text] [Related]
33. Medication-taking behaviour in Bulgarian women with postmenopausal osteoporosis treated with denosumab or monthly oral bisphosphonates.
Petranova T; Boyanov M; Shinkov A; Petkova R; Intorcia M; Psachoulia E
Arch Osteoporos; 2017 Dec; 13(1):1. PubMed ID: 29264666
[TBL] [Abstract][Full Text] [Related]
34. Preclinical and clinical efficacy of the bisphosphonate ibandronate in cancer treatment.
Bauss F; Bergström B
Curr Clin Pharmacol; 2008 Jan; 3(1):1-10. PubMed ID: 18690873
[TBL] [Abstract][Full Text] [Related]
35. Biological properties and mechanism of action of ibandronate: application to the treatment of osteoporosis.
Epstein S; Zaidi M
Bone; 2005 Oct; 37(4):433-40. PubMed ID: 16046205
[TBL] [Abstract][Full Text] [Related]
36. Quarterly intravenous injection of ibandronate to treat osteoporosis in postmenopausal women.
Sambrook P
Clin Interv Aging; 2007; 2(1):65-72. PubMed ID: 18044076
[TBL] [Abstract][Full Text] [Related]
37. Monthly oral ibandronate is well tolerated and efficacious in postmenopausal women: results from the monthly oral pilot study.
Reginster JY; Wilson KM; Dumont E; Bonvoisin B; Barrett J
J Clin Endocrinol Metab; 2005 Sep; 90(9):5018-24. PubMed ID: 15972582
[TBL] [Abstract][Full Text] [Related]
38. The optimal oral dose selection of ibandronate in Japanese patients with osteoporosis based on pharmacokinetic and pharmacodynamic properties.
Nakai K; Tobinai M; Hashimoto J; Iida S; Kawanishi T
Eur J Drug Metab Pharmacokinet; 2016 Apr; 41(2):139-47. PubMed ID: 25476995
[TBL] [Abstract][Full Text] [Related]
39. Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study.
Delmas PD; Adami S; Strugala C; Stakkestad JA; Reginster JY; Felsenberg D; Christiansen C; Civitelli R; Drezner MK; Recker RR; Bolognese M; Hughes C; Masanauskaite D; Ward P; Sambrook P; Reid DM
Arthritis Rheum; 2006 Jun; 54(6):1838-46. PubMed ID: 16729277
[TBL] [Abstract][Full Text] [Related]
40. Bisphosphonates for breast cancer.
Pavlakis N; Stockler M
Cochrane Database Syst Rev; 2002; (1):CD003474. PubMed ID: 11869664
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
